ASAna Luísa Sousa

Ana Luísa Sousa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Luísa Sousa has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Marina Magalhães

    Neurology Department, Centro Hospitalar do Porto, Porto

    3 shared publications
  • Ricardo Taipa

    Unit for Multidisciplinary Research in Biomedicine, School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal

    2 shared publications
  • Teresa Coelho

    Unidade Corino de Andrade, Unidade Local de Saúde de Santo António, Porto, Portugal

    2 shared publications
  • Ana Lopes

    Endocrinology Department, Centro Hospitalar e Universitário do Porto, EPE, Porto, Portugal

    1 shared publication
  • Ana Martins da Silva

    Unidade Corino de Andrade, Unidade Local de Saúde de Santo António, Porto, Portugal

    1 shared publication
  • Ana Paula Sousa

    Unidade Corino de Andrade, Unidade Local de Saúde de Santo António, Porto, Portugal

    1 shared publication

Latest Publications

  • Open Access

    Central nervous system manifestations in hereditary transthyretin amyloidosis: a cross-sectional study with 151 patients

    by Luísa Sousa, Teresa Coelho, Joana Fernandes, Márcio Cardoso, Cristina Alves, Ana Martins da Silva, Ana Paula Sousa, Miguel Mendonça Pinto, Rafael Maniés Pereira, Luís Ruano, et al.

    Background: Central nervous system (CNS) dysfunction is increasingly recognized in hereditary transthyretin (ATTRv) amyloidosis. We aimed to characterize CNS manifestations and assess associations with clinical variables and plasma neurofilament light chain (NfL), using history of transient focal neurological episodes (TFNEs) as the main outcome. Methods: We conducted a cross-sectional study at Unidade Corino de Andrade in Porto (January 2021–April 2023), including patients with ATTRv amyloidosis caused by the V30M mutation. History of TFNEs, stroke, seizures, headaches and symptoms/signs of cranial nerve dysfunction were assessed through patient interview and neurological examination. Plasma NfL was analyzed cross-sectionally and longitudinally (0–6–12 months). Results: 151 patients were included (56.3% male, median age 48 [IQR 44–53], with a median disease duration of 15 years [IQR 11–20]. Most had early-onset disease (94.7%). TFNE history occurred in 29.1%, headaches in 23.8%, seizures in 6.6% and stroke in 1.3%. Patients with past TFNEs had longer disease duration than those without. No other robust differences were identified. Longitudinally, pNfL levels showed an overall effect of time ( p =0.013), driven by a decrease between 6 and 12 months, with no significant differences between baseline and either follow-up timepoint. There were no differences in pNfL trajectories according to TFNEs history (time-by-TFNE interaction, p =0.416). Conclusions: The high frequency of CNS symptoms in this sample supports including CNS assessment in routine follow-up of patients with ATTRv amyloidosis with longstanding disease. Further longitudinal studies are needed to clarify determinants of CNS involvement.

  • CNS Involvement in Hereditary Transthyretin Amyloidosis

    by Luísa Sousa, Teresa Coelho, Ricardo Taipa

    Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is predominantly a disease of the peripheral nerves, heart, kidney, and eye. CNS involvement has been a marginal issue in research and the clinical setting until recently. Growing evidence shows that leptomeningeal amyloid accumulation is frequent and present from early stages of ATTRv amyloidosis. Several recent studies show CNS symptoms arise as a common late complication in patients with the V30M mutation after at least 14 years of symptomatic peripheral nerve disease. Conversely, in non-V30M patients, there are several descriptions, mostly case reports, of patients presenting with severe phenotypes of ocular and CNS dysfunction (oculoleptomeningeal amyloidosis), with little systemic involvement. This phenotype is found in rare families worldwide, associated with at least 14 mutations. In both patients with late and early onset CNS dysfunction, symptoms include transient focal neurologic episodes, hemorrhagic and ischemic stroke, cognitive decline, and cranial nerve dysfunction. Pathologically, there is severe amyloid deposition in the leptomeninges and cerebral amyloid angiopathy of leptomeningeal and penetrating vessels. These amyloid aggregates are formed mostly by CSF-produced transthyretin (TTR) and seem resistant to the available ATTRv therapies that increase the stability or reduce the production of plasma TTR. This indicates that CNS involvement will become a meaningful issue in patient management in upcoming years.


  • Open Access

    Rastreio de Polineuropatia Diabética Periférica em Doentes Internados

    by Helena Gonçalves, Ana Lopes, Andreia Costa, Joana Calvão, Liliana Fonseca, João Gonçalves, Catarina Branco, Raquel Martins, Vera Barbosa, Michel Mendes, et al.

    Introdução: A polineuropatia simétrica distal (PNSD) é umacomplicação frequente e catastrófica da diabetes mellitus, massubdiagnosticada. Os autores colocam a hipótese de o internamento ser uma oportunidade de rastreio da PNSD e pretendemcomparar dois métodos de diagnóstico.Material e Métodos: Estudo prospetivo e multicêntrico,que incluiu doentes diabéticos internados nos serviços de medicina interna de dois hospitais, entre maio e outubro de 2015.Foi aplicada a escala MNSI (Michigan Neuropathy Screening Instrument) e o teste SWME (Monofilamento de 10 g-SemmesWeinstein exam) para despiste de PNSD. Uma pontuação > 2no exame clínico da MNSI ou ≤ 7 respostas positivas em 10 noteste SWME, foram consideradas diagnósticas de DSPN.Resultados: Foram incluídos 88 pacientes com idade mediana de 77 (13) anos e 45% homens; a maioria com diabetestipo 2 e 7% tinham diagnóstico prévio de PNSD. A prevalênciade PNSD foi de 75% utilizando o MNSI; o teste SWME foi anormal em 38% destes pacientes. A taxa de concordância entre ostestes foi de 44,3%. Dos pacientes, 92,4% com diagnóstico dePNSD no estudo não tinham diagnóstico prévio.Discussão: O número de subdiagnósticos de PNSD nesteestudo é alarmante. A percentagem de casos subdiagnosticadapode representar um problema de registo ou de escassez derastreio.Conclusão: Neste estudo concluímos que a PNSD é altamente prevalente entre os pacientes hospitalizados, mas profundamente subdiagnosticada. A escala MNSI poderá ser uminstrumento adequado para o rastreio, enquanto o teste SWMEnão deve ser utilizada isoladamente para este propósito.

  • Open Access

    Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin

    by Ana L. Sousa, Paula Salgado, José E. Alves, Sara Silva, Sofia Ferreira, Marina Magalhães


  • Frontotemporal lobar degeneration‐TDP with ‘multiple system atrophy phenocopy syndrome’

    by Ana Luísa Sousa, Ricardo Taipa, Niall Quinn, Tamas Revesz, Manuel Melo Pires, Marina Magalhães


  • A Portuguese rapid-onset dystonia-parkinsonism case with atypical features

    by Ana Luísa Sousa, Isabel Alonso, Marina Magalhães